{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:51:46Z","timestamp":1793839906951,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017668","name":"Anhui Provincial Key Research and Development Plan","doi-asserted-by":"publisher","award":["2022h11020028"],"award-info":[{"award-number":["2022h11020028"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0199800"],"award-info":[{"award-number":["2022YFE0199800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104065"],"award-info":[{"award-number":["82104065"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32402413"],"award-info":[{"award-number":["32402413"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118109","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T02:27:32Z","timestamp":1756434452000},"page":"118109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Structure-guided discovery of nitrobenzo-2-oxa-1,3-diazole (NBD) scaffold-based PFKFB4 inhibitors for cancer therapy"],"prefix":"10.1016","volume":"300","author":[{"given":"Yiliang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy M.","family":"Keser\u0171","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-9132","authenticated-orcid":false,"given":"Xinya","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118109_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118109_bib2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trecan.2019.02.003","article-title":"Polytherapy and targeted cancer drug resistance","volume":"5","author":"Chatterjee","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2025.118109_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104206","article-title":"Peptides as innovative strategies to combat drug resistance in cancer therapy","volume":"29","author":"Lamb","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118109_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2025.118109_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114392","article-title":"Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies","volume":"160","author":"Hashemi","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118109_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100938","article-title":"Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms","volume":"68","author":"Li","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2025.118109_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118109_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.apsb.2023.12.003","article-title":"Targeting the Warburg effect: a revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer","volume":"14","author":"Liao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118109_bib9","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.7150\/ijbs.72534","article-title":"Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance","volume":"18","author":"Zhang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2025.118109_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2025.118109_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868695","article-title":"The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118109_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-024-01527-8","article-title":"Metabolic reprogramming in the tumor microenvironment of liver cancer","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118109_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118109_bib14","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118109_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12943-024-02165-x","article-title":"Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118109_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1479-5876-10-95","article-title":"Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation","volume":"10","author":"Telang","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118109_bib17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41419-022-05241-6","article-title":"Phosphorylation of PFKFB4 by PIM2 promotes anaerobic glycolysis and cell proliferation in endometriosis","volume":"13","author":"Lu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118109_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cmet.2018.06.017","article-title":"A glycolysis outsider steps into the cancer spotlight","volume":"28","author":"Goncalves","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2025.118109_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12935-019-0882-2","article-title":"High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer","volume":"19","author":"Yao","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2025.118109_bib20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cancers13040909","article-title":"Role of PFKFB3 and PFKFB4 in cancer: genetic basis, impact on disease development\/progression, and potential as therapeutic targets","volume":"13","author":"Kotowski","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118109_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217190","article-title":"Fibrillarin reprograms glucose metabolism by driving the enhancer-mediated transcription of PFKFB4 in liver cancer","volume":"602","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118109_bib22","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1038\/onc.2011.490","article-title":"RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival","volume":"31","author":"Goidts","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118109_bib23","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1159\/000495055","article-title":"PFKFB4 promotes breast cancer metastasis via induction of hyaluronan production in a p38-dependent manner","volume":"50","author":"Gao","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2025.118109_bib24","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.18632\/oncotarget.2213","article-title":"Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth","volume":"5","author":"Chesney","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118109_bib25","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.biochi.2005.04.007","article-title":"Overexpression of 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors","volume":"87","author":"Minchenko","year":"2005","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2025.118109_bib26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3892\/ol.2021.12557","article-title":"PFKFB4 as a promising biomarker to predict a poor prognosis in patients with gastric cancer","volume":"21","author":"Wang","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2025.118109_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111756","article-title":"Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence","volume":"41","author":"Dai","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118109_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12890-021-01420-x","article-title":"PFKFB4 promotes lung adenocarcinoma progression via phosphorylating and activating transcriptional coactivator SRC-2","volume":"21","author":"Meng","year":"2021","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ejmech.2025.118109_bib29","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmgh.2023.02.004","article-title":"PFKFB4 drives the oncogenicity in TP53-mutated hepatocellular carcinoma in a phosphatase-dependent manner","volume":"15","author":"Kam","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118109_bib30","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1038\/onc.2016.477","article-title":"6-Phosphofructo-2-kinase\/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells","volume":"36","author":"Ros","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118109_bib31","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/1078-0432.CCR-17-1475","article-title":"Etk interaction with PFKFB4 modulates chemoresistance of small-cell lung cancer by regulating autophagy","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118109_bib32","first-page":"1527","article-title":"PFKFB4 is a metabolic driver of HCC progression and chemoresistance through ROS mitigation, Cell. Mol","volume":"15","author":"Olaizola","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118109_bib33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s13046-021-02103-5","article-title":"PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance","volume":"40","author":"Feng","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118109_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.900973","article-title":"\u03b2-elemene isopropanolamine derivative LXX-8250 induces apoptosis through impairing autophagic flux via PFKFB4 repression in melanoma cells","volume":"13","author":"Jalal","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118109_bib35","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.18632\/oncotarget.4534","article-title":"Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor","volume":"6","author":"Chesney","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118109_bib36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2049-3002-1-8","article-title":"Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase\/fructose 2,6-bisphosphatases in cancer metabolism","volume":"1","author":"Ros","year":"2013","journal-title":"Cancer Metabol."},{"key":"10.1016\/j.ejmech.2025.118109_bib37","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118109_bib38","doi-asserted-by":"crossref","first-page":"D368","DOI":"10.1093\/nar\/gkad1011","article-title":"AlphaFold protein structure database in 2024: providing structure coverage for over 214 million protein sequences","volume":"52","author":"Varadi","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118109_bib39","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1110\/ps.0236803","article-title":"Can correct protein models be identified?","volume":"12","author":"Wallner","year":"2003","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2025.118109_bib40","doi-asserted-by":"crossref","first-page":"W407","DOI":"10.1093\/nar\/gkm290","article-title":"ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins","volume":"35","author":"Wiederstein","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118109_bib41","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/bioinformatics\/btz828","article-title":"QMEANDisCo\u2014distance constraints applied on model quality estimation","volume":"36","author":"Studer","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmech.2025.118109_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118109_bib43","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3390\/ph15070832","article-title":"Hepatoprotective role of carvedilol against ischemic hepatitis associated with acute heart failure via targeting miRNA-17 and mitochondrial dynamics-related proteins: an in vivo and in silico study","volume":"15","author":"Mohamed","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118109_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202109967","article-title":"Discovery and mechanism of action of small molecule inhibitors of ceramidases","volume":"61","author":"Healey","year":"2022","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.118109_bib45","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3390\/ph15121576","article-title":"Antidiabetic potential of novel 1,3,5-trisubstituted-2-thioxoimidazloidin-4-one analogues: insights into \u03b1-glucosidase, \u03b1-amylase, and antioxidant activities","volume":"15","author":"Khirallah","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118109_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1231030","article-title":"Unveiling the antitumor potential of novel N-(substituted-phenyl)-8-methoxycoumarin-3-carboxamides as dual inhibitors of VEGFR2 kinase and cytochrome P450 for targeted treatment of hepatocellular carcinoma","volume":"11","author":"Radwan","year":"2023","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2025.118109_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12752","article-title":"The cellular ceramide transport protein CERT promotes Chlamydia psittaci infection and controls bacterial sphingolipid uptake","volume":"19","author":"Koch-Edelmann","year":"2017","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118109_bib48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13065-023-01063-5","article-title":"Novel 8-methoxycoumarin-3-carboxamides with potent anticancer activity against liver cancer via targeting caspase-3\/7 and \u03b2-tubulin polymerization","volume":"17","author":"Alzamami","year":"2023","journal-title":"BMC Chem"},{"key":"10.1016\/j.ejmech.2025.118109_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114849","article-title":"Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77","volume":"244","author":"Qin","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:58:59Z","timestamp":1772830739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"alternative-id":["S0223523425008748"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118109","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided discovery of nitrobenzo-2-oxa-1,3-diazole (NBD) scaffold-based PFKFB4 inhibitors for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118109"}}